Conversations

network building in the Big Data Deluge

Sage Bionetworks is holding an interactive colloquium with the Hutchinson Cancer Research Center on collective approaches to analyzing the tsunami of medical research data and translate it into healthcare advances. Come find out what you need to take advantage of high performance, cloud-based computing and the development of predictive models of disease within a collaborative platform.

Presentations and Roundtable:
FHCRC – david hockenbery • soheil meshinchi • pete nelson • jim olson • riki peters • jerry radich
UW – kelly edwards
SAGE BIONETWORKS – jonathan derry • stephen friend • erich huang • lara mangravite • adam margolin
GUEST SPEAKER – eric schadt
synapse demonstrations • sage bionetworks software platform team
poster presentations • sage bionetworks scientists & engineers

Questions? contact conversations@sagebase.org

Monday 23 January 2012 – 2 PM – 5 PM

Pelton Auditorium • Thomas Building • Fred Hutchinson Cancer Research Center • 1100 Fairview Ave. N. • Seattle WA

Download PDF of Program

More Genomics Current Events Reading

Sage Bionetworks
Stephen Friend has published a short editorial/review on the Sage Commons Congress in the new journal Science Translational Medicine.  It connects Sage Bionetworks’ vision and mission with the activities of the April meeting.  Free access is available on the Sage Bionetworks News page.

Nature Biotechnology continues to follow new industry trends in its July 2010 issue.  Stephen Strauss contributed an article entitled, “Pharma Embraces Open Source Models” that highlights Sage’s progressive pharmaceutical partnerships.

DIY Genomics
The fledgling Direct to Consumer (DTC) genomics industry encountered a congressional tempest in Washington DC last week with the release of a highly critical GAO report and subsequent committee hearings.  The report is available on line and there are several insightful commentaries from National Public Radio, Natasha Singer in The New York Times, Dan Vorhaus, Daniel MacArthur and David Ewing Duncan in Fortune.com as well as a rebuttal from 23 and me.